MedPath

Darotropium Bromide

Generic Name
Darotropium Bromide
Clinical Trials
Related News

Phase I Study of GSK233705 in Healthy Japanese Male Subjects

Phase 1
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: Placebo
First Posted Date
2009-08-24
Last Posted Date
2017-08-03
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
28
Registration Number
NCT00964405
Locations
🇯🇵

GSK Investigational Site, Fukuoka, Japan

A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects

Phase 1
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: GW642444
Drug: GSK233705 and GW642444
Drug: Placebo
First Posted Date
2008-10-31
Last Posted Date
2017-07-18
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
16
Registration Number
NCT00783003
Locations
🇬🇧

GSK Investigational Site, Stepney Green, United Kingdom

A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects.

Phase 1
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: GW642444
Drug: GSK233705 and GW642444
Drug: Placebo
First Posted Date
2008-05-05
Last Posted Date
2017-10-04
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
16
Registration Number
NCT00671216
Locations
🇬🇧

GSK Investigational Site, London, United Kingdom

Study To Examine Safety, Tolerability And Pharmacokinetics Of Intravenous Doses And Oral Dose Of GSK233705

Phase 1
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
First Posted Date
2007-07-12
Last Posted Date
2017-08-07
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
9
Registration Number
NCT00500461
Locations
🇬🇧

GSK Investigational Site, London, United Kingdom

A Dose Ascending, Study To Examine The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of GSK233705B.

Phase 2
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
First Posted Date
2007-03-29
Last Posted Date
2018-03-12
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
23
Registration Number
NCT00453479
Locations
🇳🇱

GSK Investigational Site, Zuidlaren, Netherlands

A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK233705 In Healthy Volunteers.

Phase 1
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
First Posted Date
2007-03-29
Last Posted Date
2017-08-07
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
12
Registration Number
NCT00453687
Locations
🇺🇸

GSK Investigational Site, Baltimore, Maryland, United States

Safety And Efficacy Of GSK233705 Plus Salmeterol Compared With 2 Active Comparators And Placebo In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Phase 2
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
First Posted Date
2007-01-17
Last Posted Date
2016-10-28
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
60
Registration Number
NCT00422604
Locations
🇬🇧

GSK Investigational Site, Manchester, United Kingdom

Safety And Tolerability Study In Patients With Chronic Obstructive Pulmonary Disease

Phase 2
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
First Posted Date
2006-09-15
Last Posted Date
2018-06-07
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
45
Registration Number
NCT00376714
Locations
🇸🇪

GSK Investigational Site, Lund, Sweden

Safety Study Using GSK233705 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease

Phase 1
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: Placebo
First Posted Date
2006-01-19
Last Posted Date
2017-09-25
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
31
Registration Number
NCT00279019
Locations
🇩🇪

GSK Investigational Site, Berlin, Germany

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy